erhui1979 / iStockphoto.com
As CEO of the UK BioIndustry Association, Steve Bates works closely with industry and government and, by 2025, he wants the UK to become home to the third biggest global biotech cluster, as he explains to LSIPR.
From working as senior director at Genzyme to advising the UK government, Steve Bates has had a varied career, and he’s certainly no stranger to influencing public policy.
Since 2012, he’s settled into the role of CEO of the UK BioIndustry Association (BIA), a trade body founded more than 20 years ago at the infancy of biotechnology.
Bates has been involved in major BIA campaigns for improved access to finance, the extension of the UK Biomedical Catalyst (BMC), anti-microbial resistance and the opportunity the sector presents to long-term investors.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Steve Bates, UK BioIndustry Association, BIA, industry, Brexit, UK biotech sector, LSIPR, BioIndustry, government
